CNA Diagnostics Inc. and Partners Awarded Non-Dilutive Funds to Pursue Development of High Throughput Diagnostic Equipment

June 22, 2017 / by news release

CALGARY, ALBERTA, June 22, 2017, CNA Diagnostics Inc. (”CNAD”, the “Corporation” or the “Company”) is pleased to announce it, in combination with its German partners Metabion GmbH and Becker & Hickl GmbH, has been awarded approximately $800,000 CAD from the Alberta and German governments to pursue development of a high throughput, rapid testing diagnostic machine.

As part of the agreement, CNAD will invest $125,000 CAD to compare its Polymerase Chain Reaction (PCR) assay with the prototype machine in a field setting. The prototype machine is expected to be used in conjunction with CNAD’s DNA biomarkers specific for Bovine Respiratory Disease (“BRD”) with the ultimate objective to commercialize a low cost, rapid test that accurately identifies the most economically significant disease impacting beef cattle upon entry to the feedlot.

Current PCR machines are a powerful scientific tool; however, costs to operate are inefficient for use on a mass scale and the equipment takes over an hour to complete a batch of tests.

CNAD plans to establish the study’s baseline by conducting the PCR based tests specific to BRD in the fall of 2017 with the support of Feedlot Health Management Services and pilot the new equipment during the fall of 2018.

“We are pleased with the award of non-dilutive financing to support our development of a low cost, rapid diagnostic solution to Bovine Respiratory Disease” stated David Gordon, CEO. “In combination with our BRD biomarkers, such equipment will benefit the beef industry enormously. It will lead to lower feedlot morbidity and mortality, higher production per animal and lower the use of antibiotics, potentially eliminating the need for mass broadcasting of antibiotics to animals in the feedlot.”

About CNA Diagnostics Inc.:

CNAD’s researches diagnostic markers that identifies when an animal or human is developing certain diseases before the disease can be detected by existing methods. The Company develops, patents and plans to commercialize high-sensitivity and specificity, molecular diagnostic technologies for subclinical detection of major diseases of food producing animals, companion animal and humans.

For more information, please contact:

David Gordon
Chief Executive Officer
david@cnadiagnostics.com
Tel: +1 403 910 1834

Forward-Looking Information Advisory

Certain information in this press release is forward-looking within the meaning of certain securities laws, and is subject to important risks, uncertainties and assumptions. This forward-looking information includes, among other things, information with respect to the Corporate Changes, Private Placement and shares for debt transactions, assumptions about future economic conditions and courses of action, and the Company's beliefs, plans, expectations, anticipations, estimates and intentions. The words "may", "could", "should", "would", "suspect", "outlook", "believe", "anticipate", "estimate", "expect", "intend", "plan", "target" and similar words and expressions are used to identify forward-looking information. The forward-looking information in this material change report describes the Company's expectations as of the date of this news release and accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While the Company may elect to, it does not undertake to update this information at any particular time.